Okyo files for FDA clearance to start trial of dry eye disease therapy

Nov. 21, 2022 5:34 AM ETOKYO Pharma Limited (OKYO)EMMLFBy: Ravikash, SA News Editor

Light beam is shining through retina and lens on eyesight exam

Zorica Nastasic

Okyo Pharma (NASDAQ:OKYO) said it filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) seeking clearance to start a trial of OK-101 to treat dry eye disease (DED).

The London-based company

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.